Earnings
Home›Earnings›Guidance›MiniMed raises full-year organic revenue outlook to ab…
MiniMed raises full-year organic revenue outlook to about 10.5%
The quarter showed 16.6% worldwide net sales growth, but free cash flow fell to negative $90 million as separation and launch costs weighed on results.
MiniMed Group reported fiscal 2027 first-quarter results for the period ended July 31, 2026, with worldwide net sales rising 16.6% to $843 million, and management raised full-year organic revenue growth guidance to approximately 10.5% from 10%. U.S. net sales grew 13.1%, while worldwide organic growth was 15.8%, according to Yahoo Finance.
Analysts cited pipeline progress alongside the guidance increase. BofA lifted its target to $28 from $24, calling the quarter a solid beat with pipeline updates as the main highlight, while Mizuho raised its target to $26 from $21, pointing to momentum from Flex pumps and newer sensors, Yahoo Finance reported.
Despite the revenue and guidance momentum, the cash flow picture lagged, with adjusted EBITDA margin at 9.9% and free cash flow of negative $90 million for the quarter. Yahoo Finance noted that $111 million of the cash burn came from separation and standup costs related to building MiniMed into an independent company, which would have left free cash flow positive by $21 million without those items.
The operating details also included margin pressure from $8 million in pulled-forward spending to accelerate the Fit filing and Flex launch, plus a $12 million currency remeasurement charge, which together reduced about 230 basis points off EBITDA margin. Yahoo Finance added that new pumps sold in the U.S. climbed more than 20% year over year, and the company’s global CGM attachment rate reached 69%, up from 64% a year earlier.